Author

P. P. Roger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

E. Raspe· 2 shared F. Libert· 2 shared M. Tarabichi· 2 shared B. M. Cavaco· 1 shared C. Blanquart· 1 shared C. Durante· 1 shared C. Maenhaut· 1 shared C. Meiller· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

E. Raspe

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

J. M. Pita, E. Raspe, K. Coulonval, M. Decaussin-Petrucci, M. Tarabichi, G. Dom, F. Libert, L. Craciun, G. Andry, L. Wicquart, E. Leteurtre, C. Tresallet, L. A. Marlow, J. A. Copland, C. Durante, , P. P. Roger

This study shows that CDK4 phosphorylation status predicts response to CDK4/6 inhibitors in thyroid carcinomas and supports combining them with BRAF/MEK inhibitors to prevent resistance.

bioRxiv · Jun 5, 2023Cancer Biology

Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of malignant pleural mesotheliomas to CDK4/6 inhibition

S. Paternot, E. Raspe, C. Meiller, M. Tarabichi, J.-B. Assie, F. Libert, M. Remmelink, X. Bisteau, P. Pauwels, Y. Blum, N. Le Stang, S. Tabone-Eglinger, F. Galateau-Salle, C. Blanquart, J. P. Van Meerbeeck, , P. P. Roger

This study shows that CDK4 phosphorylation predicts sensitivity of malignant pleural mesothelioma to CDK4/6 inhibitors, with 80% of tumors expressing phosphorylated CDK4.

bioRxiv · Apr 11, 2022Cancer Biology